PIP-MMAE

**PIP-MMAE** is a peptide-drug conjugate (PDC) designed for targeted cancer therapy, consisting of a peptide ligand (likely targeting a specific tumor antigen via PIP, possibly referring to a prostate-specific or peptide-based targeting moiety) conjugated to **monomethyl auristatin E (MMAE)**, a highly potent antimitotic cytotoxin. MMAE inhibits cell division by binding tubulin and preventing microtubule polymerization, derived from dolastatin analogs and 100-1000 times more potent than doxorubicin, but too toxic for systemic use alone. In PDCs or antibody-drug conjugates (ADCs), it is delivered selectively to cancer cells expressing the target, where lysosomal enzymes like cathepsin cleave the linker to release free MMAE, inducing apoptosis while minimizing off-target toxicity.[1][4]